DBV DBV Technologies SA

Information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2024

Information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2024

Information regarding the total number of voting rights and

total number of shares of the Company as of May 31, 2024

(Article 223-16 of the General Regulations of the Autorité des Marchés Financiers)

Market : NYSE Euronext Paris

ISIN Code: FR 0010417345

 



Date



 		Total number of shares Total number of voting rights
05/31/2024



 		96,493,078



 		 



Total gross of voting rights: 96,493,078



 
 



Total net* of voting rights: 96,236,383



 

* Net total = total number of voting rights attached to shares – shares without voting rights

Attachment



EN
04/06/2024

Underlying

DBVDBV Technologies SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DBV Technologies SA

 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Technologies to Participate in the Goldman Sachs 45th Annual Globa...

DBV Technologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference Châtillon, France, June 5, 2024 DBV Technologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today announced that Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the 45th Annual Goldman Sac...

June 5, 2024 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Technologies participera à la 45e conférence annuelle Goldman Sach...

DBV Technologies participera à la 45e conférence annuelle Goldman Sachs Global Healthcare Châtillon, France, le 5 juin (22 :30 CEST) 2024 DBV Technologies participera à la 45e conférence annuelle Goldman Sachs Global Healthcare DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT—CUSIP: 23306J101), société biopharmaceutique au stade clinique spécialisée dans les options de traitement des allergies alimentaires et d'autres conditions immunologiques dont les besoins médicaux ne sont pas satisfaits, a annoncé aujourd'hui que Daniel Tassé, Directeur Général, parti...

June 5, 2024 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

Information regarding the total number of voting rights and total num...

Information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2024 Information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2024 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345  Date  Total number of shares Total number of voting rights05/31/2024 96,493,078  Total gross of voting rights: 96,493,078  Total net* of voting rights: 96,236,383  * Net total = total number of voting rights attached to sh...

June 4, 2024 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Technologies Announces Plan to Implement ADS Ratio Change

DBV Technologies Announces Plan to Implement ADS Ratio Change Châtillon, France, May 31, 2024 DBV Technologies Announces Plan to Implement ADS Ratio Change DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT—CUSIP: 23306J101), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, previously announced plans to change the ratio of its American Depositary Shares (“ADSs”) to its ordinary shares (the “ADS Ratio”), nominal value €0.10 (ten cents) per share, fro...

May 31, 2024 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Technologies to Participate in Upcoming EAACI 2024 Congress

DBV Technologies to Participate in Upcoming EAACI 2024 Congress Châtillon, France, May 30, 2024 DBV Technologies to Participate in Upcoming EAACI 2024 Congress DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today announced its upcoming participation in the European Academy of Allergy and Clinical Immunology (EAACI) Congress May 31 – June 3 in Valencia, Spain. A flash talk presentation by Nicol...

May 30, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch